Charles River Laboratories International, Inc. (NYSE:CRL) Stake Increased by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 2,531.9% in the second quarter, Holdings Channel reports. The institutional investor owned 2,395 shares of the medical research company’s stock after acquiring an additional 2,304 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Charles River Laboratories International were worth $886,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Charles River Laboratories International by 14.6% in the second quarter. Vanguard Group Inc. now owns 5,911,634 shares of the medical research company’s stock worth $2,186,831,000 after buying an additional 754,558 shares during the last quarter. FMR LLC increased its stake in Charles River Laboratories International by 26.0% during the second quarter. FMR LLC now owns 2,558,406 shares of the medical research company’s stock valued at $946,406,000 after purchasing an additional 527,728 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Charles River Laboratories International by 4.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,438,409 shares of the medical research company’s stock valued at $532,096,000 after purchasing an additional 59,970 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in Charles River Laboratories International by 15.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,261,319 shares of the medical research company’s stock valued at $365,568,000 after purchasing an additional 169,486 shares during the last quarter. Finally, William Blair Investment Management LLC increased its stake in Charles River Laboratories International by 657.7% during the first quarter. William Blair Investment Management LLC now owns 992,180 shares of the medical research company’s stock valued at $287,564,000 after purchasing an additional 861,234 shares during the last quarter. Institutional investors and hedge funds own 93.28% of the company’s stock.

CRL stock opened at $402.83 on Thursday. The company has a market capitalization of $20.30 billion, a P/E ratio of 51.91, a PEG ratio of 3.07 and a beta of 1.14. The company has a 50-day simple moving average of $426.80 and a 200 day simple moving average of $374.84. Charles River Laboratories International, Inc. has a fifty-two week low of $219.79 and a fifty-two week high of $460.21. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 1.17.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Tuesday, August 3rd. The medical research company reported $2.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.23. Charles River Laboratories International had a net margin of 12.10% and a return on equity of 23.59%. The company had revenue of $914.61 million during the quarter, compared to the consensus estimate of $880.72 million. During the same period in the prior year, the company earned $1.58 EPS. Charles River Laboratories International’s revenue was up 34.0% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.25 EPS for the current year.

Several research firms have weighed in on CRL. Evercore ISI reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday. Argus boosted their target price on shares of Charles River Laboratories International from $390.00 to $480.00 and gave the company a “buy” rating in a research note on Monday, August 23rd. Wells Fargo & Company boosted their target price on shares of Charles River Laboratories International from $375.00 to $470.00 and gave the company an “overweight” rating in a research note on Thursday, August 5th. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $410.00 to $461.00 and gave the company an “outperform” rating in a research note on Thursday, August 5th. Finally, UBS Group boosted their price target on shares of Charles River Laboratories International from $390.00 to $465.00 and gave the company a “buy” rating in a report on Tuesday, August 17th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $400.79.

In other Charles River Laboratories International news, VP Birgit Girshick sold 81 shares of the company’s stock in a transaction dated Monday, September 13th. The shares were sold at an average price of $442.19, for a total value of $35,817.39. Following the completion of the sale, the vice president now directly owns 30,025 shares of the company’s stock, valued at approximately $13,276,754.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP William D. Barbo sold 12,387 shares of the company’s stock in a transaction dated Friday, August 6th. The shares were sold at an average price of $402.82, for a total transaction of $4,989,731.34. Following the completion of the sale, the vice president now directly owns 4,371 shares of the company’s stock, valued at $1,760,726.22. The disclosure for this sale can be found here. Insiders sold a total of 40,900 shares of company stock valued at $16,673,320 over the last three months. 1.20% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Read More: What are the advantages to having securities held in street name?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.